自身免疫性甲状腺疾病对类风湿关节炎疾病活动度及甲氨蝶呤应答的影响
诊断时合并AITD者患者报告结局指标更高但客观活动指标无差异,DAS28仅轻微升高(5.2 vs 5.1);整体EULAR应答不受影响,但45岁以下患者中AITD可能与3个月和6个月EULAR非/中度应答相关。
要点
- 合并AITD的RA患者诊断时患者报告结局更差,但客观疾病活动指标无显著差异。
- AITD整体不影响甲氨蝶呤治疗3个月和6个月的EULAR应答。
- 45岁以下患者中AITD可能与甲氨蝶呤原发应答不佳相关。
核心结论
- 诊断时合并AITD的RA患者患者报告结局指标更差,但客观疾病活动指标无差异,DAS28仅轻微升高。
- 整体EULAR良好应答率在3个月和6个月不受AITD影响,但年轻患者亚组中AITD可能预测原发应答不佳。
研究设计与样本
- 采用logistic回归比较合并与不合并AITD患者的DAS28及其组分和EULAR应答。
主要发现
- 诊断时合并AITD的RA患者患者全局评估、HAQ-DI和疼痛评分显著更高(p<0.05),但ESR和肿胀关节数无显著差异。
- 合并与不合并AITD患者DAS28水平分别为5.2和5.1。
- AITD对3个月EULAR应答影响很小(非/中度应答OR=0.95,95%CI 0.8-1.1),6个月亦无影响。
- 按年龄分层,45岁以下患者中AITD在3个月和6个月EULAR非/中度应答者中更常见,OR分别为1.44(0.76-2.76)和2.75(1.04-7.28)。
关键数值与推荐
- AITD定义为RA诊断前开具甲状腺素处方,排除非自身免疫性原因。
- EULAR应答评估基于DAS28,非/中度应答OR=0.95(95%CI 0.8-1.1)对应3个月甲氨蝶呤治疗。
- 45岁以下患者3个月非/中度应答OR=1.44(95%CI 0.76-2.76),6个月OR=2.75(95%CI 1.04-7.28)。
临床怎么用
- 对合并AITD的RA患者,应关注患者报告的症状负担,尽管客观炎症指标可能无明显升高。
- 甲氨蝶呤治疗应答整体不受AITD影响,但45岁以下合并AITD患者需警惕原发应答不佳可能。
局限性
- AITD定义基于甲状腺素处方,可能遗漏未治疗或使用其他治疗方式的患者。
- 年轻患者亚组分析样本量有限,OR置信区间较宽,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate if autoimmune thyroid disease (AITD) impacts rheumatoid arthritis (RA) disease activity or response to methotrexate. METHODS: A nationwide register-based cohort study of 9 004 patients with new-onset RA from the Swedish Rheumatology Quality Register year 2006-2016, with linkage to other nationwide registers to identify comorbidity with AITD defined as thyroxine prescription before RA diagnosis, excluding non-autoimmune causes. We compared RA disease activity using 28-joint Disease Activity Score (DAS28) and its components, and EULAR response, between patients with and without AITD, using logistic regression. RESULTS: At diagnosis, patient reported outcome measures (PROMs; patient global, Health Assessment Questionnaire Disability Index and pain) but not objective disease activity measures (erythrocyte sedimentation rate and swollen joint count) were significantly higher (p<0.05 for all PROMs) among RA patients with AITD compared with those without. The level of DAS28 was 5.2 vs 5.1. By contrast, AITD had little influence on EULAR response to methotrexate at 3 months (OR of non/moderate response=0.95, 95% CI 0.8 to 1.1), nor at 6 months. When stratified by age, however, AITD was more common among EULAR non/moderate responders at 3 and 6 months in patients below 45 years resulting in ORs of non/moderate response of 1.44 (0.76-2.76) and 2.75 (1.04-7.28). CONCLUSION: At diagnosis, RA patients with concomitant AITD score worse on patient reported but not on objective RA disease activity measures, while DAS28 was only marginally elevated. The overall chance of achieving a EULAR good response at 3 or 6 months remains unaffected, although among a limited subgroup of younger patients, AITD may be a predictor for an inferior primary response.
引用
- Waldenlind K, Delcoigne B, Saevarsdottir S, et al. Does autoimmune thyroid disease affect rheumatoid arthritis disease activity or response to methotrexate? RMD Open. 2020. PMID: 32669456. doi:10.1136/rmdopen-2020-001282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。